Febuxostat is not associated with worse cardiovascular safety outcomes or all-cause mortality compared to allopurinol
1. Febuxostat was non-inferior to allopurinol for primary cardiovascular endpoints including hospitalization for non-fatal myocardial infarction or biomarker-positive acute coronary ...